Stemline Therapeutics Inc Quick Ratio (STML) starting from the first quarter 2020 to first quarter 2019, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Stemline Therapeutics Inc  (STML)

Stemline Therapeutics Inc's Quick Ratio

STML's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the first quarter 2020, Quick Ratio deteriorated to 6.66 below Stemline Therapeutics Inc's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 169 other companies have achieved higher Quick Ratio than Stemline Therapeutics Inc in first quarter 2020. While Quick Ratio total ranking in the first quarter 2020 has deteriorated compared to the prior quarter from 463 to 490.

Explain Quick Ratio?
How much Cash & cash equivalents STML´s has?
What are STML´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

STML Quick Ratio (Mar 31 2020)
Q1		 (Dec 31 2019)
Q4		 (Sep 30 2019)
Q3		 (Jun 30 2019)
Q2		 (Mar 31 2019)
Q1
Y / Y Current Liabilities Change -13.94 % 9.02 % 29.49 % 46.55 % 35.01 %
Y / Y Cash & cash equivalent Change 21.85 % 173.57 % 122.24 % 8.05 % 24.97 %
Quick Ratio MRQ 6.66 7.11 7.77 3.88 4.7
STML's Total Ranking # 490 # 463 # 301 # 357 # 677
Seq. Current Liabilities Change -1.62 % 3.05 % -16.23 % 1.34 % 24.62 %
Seq. Cash & cash equivalent Change -7.85 % -5.79 % 68.01 % -16.46 % 106.89 %



Quick Ratio first quarter 2020 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 170
Healthcare Sector # 252
Overall Market # 490


Quick Ratio Statistics
High Average Low
30.75 8.29 2.61
(Sep 30 2013)   (Dec 31 2017)




Financial Statements
Stemline Therapeutics Inc's Current Liabilities $ 23 Millions Visit STML's Balance sheet
Stemline Therapeutics Inc's Cash & cash equivalent $ 152 Millions Visit STML's Balance sheet
Source of STML's Sales Visit STML's Sales by Geography


Cumulative Stemline Therapeutics Inc's Quick Ratio

STML's Quick Ratio for the trailling 12 Months

STML Quick Ratio

 (Mar 31 2020)
12 Months		 (Dec 31 2019)
12 Months		 (Sep 30 2019)
12 Months		 (Jun 30 2019)
12 Months		 (Mar 31 2019)
12 Months
Y / Y Current Liabilities TTM Growth 14.23 % 29.3 % 29.13 % 27.18 % 22.87 %
Y / Y Cash & cash equivalent TTM Growth 65.5 % 69.67 % 42.03 % 17.25 % 27.88 %
Quick Ratio TTM 6.25 5.74 4.78 4 4.31
Total Ranking TTM # 4396 # 4438 # 404 # 549 # 4564
Seq. Current Liabilities TTM Growth -3.73 % 1.97 % 5.57 % 10.22 % 8.97 %
Seq. Cash & cash equivalent TTM Growth 4.79 % 22.54 % 26.17 % 2.16 % 7.43 %

Quick ratio ranking by company, industry and sector >> Back to STML Financial Strength Comparisons >> Go to Compare STML Quick Ratio to its Competitors

On the trailing twelve months basis STML Cash & cash equivalent grew by 21.85 % in Q1 2020 year on year, while Current Liabilities decreased to $23 millions, this led to increase in in Stemline Therapeutics Inc's Quick Ratio to 6.25, Quick Ratio remained below STML average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 475 other companies have achieved higher Quick Ratio than Stemline Therapeutics Inc. While Quick Ratio overall ranking has improved so far to 4396, from total ranking during the twelve months ending fourth quarter 2019 at 4438.

Explain Quick Ratio?
How much Cash & cash equivalents STML´s has?
What are STML´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 476
Healthcare Sector # 898
Within the Market # 4396


trailing twelve months Quick Ratio Statistics
High Average Low
13.23 6.41 4
(Jun 30 2015)   (Jun 30 2019)




Companies with similar Quick Ratio in the quarter ending Mar 31 2020, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2020 MRQ Cash & cash equivalentMar 31 2020 MRQ Current Liabilities
Revance Therapeutics Inc   18.31 $ 511.270  Millions$ 27.929  Millions
Applied Therapeutics Inc   18.23 $ 154.309  Millions$ 8.466  Millions
Kezar Life Sciences Inc   18.22 $ 123.350  Millions$ 6.771  Millions
Viela Bio Inc   18.19 $ 314.830  Millions$ 17.309  Millions
Scpharmaceuticals Inc   17.76 $ 75.339  Millions$ 4.242  Millions
Principia Biopharma Inc   17.28 $ 311.469  Millions$ 18.021  Millions
Enlivex Therapeutics Ltd  17.11 $ 54.784  Millions$ 3.201  Millions
Rapt Therapeutics Inc   16.98 $ 228.178  Millions$ 13.442  Millions
Synlogic Inc   16.75 $ 114.249  Millions$ 6.819  Millions
Oric Pharmaceuticals Inc   16.62 $ 79.442  Millions$ 4.780  Millions
Madrigal Pharmaceuticals Inc   16.09 $ 408.510  Millions$ 25.384  Millions
Deciphera Pharmaceuticals Inc   15.87 $ 691.500  Millions$ 43.571  Millions
Epizyme Inc.  15.68 $ 376.461  Millions$ 24.004  Millions
Anaptysbio Inc   15.59 $ 362.483  Millions$ 23.250  Millions
Lunai Bioworks Inc   15.51 $ 10.939  Millions$ 0.705  Millions
Kura Oncology Inc   14.91 $ 216.935  Millions$ 14.554  Millions
Cymabay Therapeutics Inc   14.78 $ 176.232  Millions$ 11.922  Millions
Diamedica Therapeutics Inc   14.61 $ 12.843  Millions$ 0.879  Millions
Crescent Biopharma Inc   14.59 $ 154.875  Millions$ 10.612  Millions
Intra cellular Therapies Inc   14.45 $ 448.954  Millions$ 31.076  Millions
Ideaya Biosciences Inc   14.24 $ 87.863  Millions$ 6.170  Millions
Trevena inc   14.22 $ 28.090  Millions$ 1.975  Millions
Cytokinetics Incorporated  14.05 $ 220.706  Millions$ 15.711  Millions
Bridgebio Pharma Inc   13.94 $ 905.175  Millions$ 64.914  Millions
Satsuma Pharmaceuticals Inc   13.93 $ 100.780  Millions$ 7.233  Millions
Cryoport inc   13.85 $ 97.916  Millions$ 7.070  Millions
Seres Therapeutics Inc   13.60 $ 75.094  Millions$ 5.521  Millions
Savara Inc   13.58 $ 104.987  Millions$ 7.729  Millions
Lixte Biotechnology Holdings Inc   13.58 $ 2.185  Millions$ 0.161  Millions
Apellis Pharmaceuticals Inc   13.47 $ 646.694  Millions$ 48.008  Millions

Date modified: 2026-09-26T07:14:03+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.